Abstract: Novel ?-lactams finding utility as intermediates in the preparation of sidechain-bearing taxanes such as taxol and taxol derivatives. The present invention also relates to novel methods of coupling ?-lactams to form such sidechain-bearing taxanes, and to novel sidechain-bearing taxanes.
Type:
Grant
Filed:
October 20, 2004
Date of Patent:
February 13, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
John K. Thottathil, Ivan D. Trifunovich, David J. Kucera, Wen-Sen Li
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
October 19, 2005
Date of Patent:
December 19, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ashvinikumar V. Gavai, Wen-Ching Han, Yufen Zhao, Ping Chen
Abstract: The present invention is directed to a transfer device for fluid communication between a first site and a second site comprising a housing, a fluid channel and typically a sleeve assembly. The housing has a first end being connectable to the first site, a second end being connectable to the second site and a longitudinal portion extending between the first and second ends and defining a longitudinal axis. The housing includes two oppositely arranged wings comprising engaging means for engagement with the first site. The fluid channel is provided in the housing for fluid communication between the first end and the second end of the housing. The optionally provided sleeve assembly is mounted to the housing and axially movable relative to and biased against the housing.
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
July 27, 2005
Date of Patent:
September 26, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
June 14, 2005
Date of Patent:
September 5, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Zhen-wei Cai, Louis J. Lombardo, Rajeev S. Bhide, Ligang Qian, Donna D. Wei, Stephanie Barbosa
Abstract: The present invention provides a process for preparing compounds of formula (I) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Type:
Grant
Filed:
December 9, 2004
Date of Patent:
September 5, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Shankar Swaminathan, Ashvinikumar V. Gavai, Junying Fan, Bharat P. Patel, Derek J. Norris, Richard Michael Corbett, Bin Zheng
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
June 21, 2005
Date of Patent:
September 5, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ashvinikumar V. Gavai, Harold Mastalerz, Jean-Paul Daris, Pierre Dextraze, Philippe Lapointe, Edward H. Ruediger, Dolatrai M. Vyas, Guifen Zhang
Abstract: The present invention provides compounds of formula I or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof and compounds of the formula or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
September 1, 2004
Date of Patent:
August 8, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Xiaopeng Sang, Xuhua Karen Du, John F. Kadow
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
June 18, 2003
Date of Patent:
August 1, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
Abstract: A method for the resolution of a mixture of the cis or trans enantiomers of a compound of the formula wherein R1 is —O—C(O)alkyl, —O—C(O)aryl or —O—C(O)cycloalkyl by contacting the mixture with a carboxylic ester hydrolase enzyme which catalyzes the stereoselective hydrolysis of the mixture and the use of such enantiomers to produce antitumor compounds which are especially suitable for oral administration.
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Type:
Grant
Filed:
December 22, 2004
Date of Patent:
June 20, 2006
Assignee:
Bristol Myers Squibb Company
Inventors:
Ashvinikumar V. Gavai, Wen-Ching Han, Ping Chen, Edward H. Ruediger, Harold Mastalerz, Brian E. Fink, Derek J. Norris
Abstract: Disclosed are pyrrolopyridazine compounds of the formula, wherein the substituents are defined herein, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
Type:
Grant
Filed:
September 26, 2003
Date of Patent:
April 18, 2006
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, Carl R. Illig, Kenneth Jerome Wilson, Jinsheng Chen, Sanath K. Meegalla, Mark James Wall
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
May 18, 2000
Date of Patent:
January 3, 2006
Assignee:
Bristol Myers Squibb Company
Inventors:
John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
July 18, 2003
Date of Patent:
November 29, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Rajeev S. Bhide, Rejean Ruel, Carl Thibault, Alexandre L'Heureux
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Abstract: The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
July 18, 2003
Date of Patent:
August 23, 2005
Assignee:
Bristol Myers Squibb Company
Inventors:
Rajeev S. Bhide, Junying Fan, Luca Parlanti, Stephanie Barbosa, Ligang Qian, Zhen-Wei Cai, Francis S. Gibson
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
December 15, 2003
Date of Patent:
July 12, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
November 14, 2002
Date of Patent:
June 21, 2005
Assignee:
Bristol Myers Squibb Company
Inventors:
Harold Mastalerz, Guifen Zhang, James G. Tarrant, Gregory D. Vite
Abstract: Disclosed are pyrrolopyridazine compounds of the formula, wherein the substituents are defined herein, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
Type:
Grant
Filed:
March 25, 2003
Date of Patent:
May 31, 2005
Assignee:
Bristol Myers Squibb Company
Inventors:
Mark Salvati, Stephanie A. Barbosa, Zhong Chen, John T. Hunt